PDCD1 and neoplasm: CAR-T cells that secrete PD-1-blocking scFV into the local environment to block PD-1 on CAR-T cells and bystander tumor-specific T cells outperformed CAR-T cells that were combined with PD-1 blocking monoclonal antibody treatment, highlighting the role of the localized application of PD-1 blockers [105].